CN204479593U - Based on the injury of kidney detection kit of biomarker - Google Patents
Based on the injury of kidney detection kit of biomarker Download PDFInfo
- Publication number
- CN204479593U CN204479593U CN201520168552.3U CN201520168552U CN204479593U CN 204479593 U CN204479593 U CN 204479593U CN 201520168552 U CN201520168552 U CN 201520168552U CN 204479593 U CN204479593 U CN 204479593U
- Authority
- CN
- China
- Prior art keywords
- reagent tube
- antibody
- detection
- biomarker
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 158
- 239000000090 biomarker Substances 0.000 title claims abstract description 82
- 230000006378 damage Effects 0.000 title claims abstract description 49
- 210000003734 kidney Anatomy 0.000 title claims abstract description 44
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 41
- 208000014674 injury Diseases 0.000 title claims abstract description 41
- 108010051335 Lipocalin-2 Proteins 0.000 claims abstract description 78
- 102000013519 Lipocalin-2 Human genes 0.000 claims abstract description 78
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 claims abstract description 72
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 claims abstract description 72
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 claims abstract description 72
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 72
- 101800001015 Glycocalicin Proteins 0.000 claims abstract description 51
- 102400000446 Glycocalicin Human genes 0.000 claims abstract description 51
- 102000004266 Collagen Type IV Human genes 0.000 claims abstract description 50
- 108010042086 Collagen Type IV Proteins 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 24
- 239000000758 substrate Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000029918 bioluminescence Effects 0.000 claims description 12
- 238000005415 bioluminescence Methods 0.000 claims description 12
- 239000012857 radioactive material Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000012086 standard solution Substances 0.000 claims description 10
- 238000007689 inspection Methods 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- CMZYGFLOKOQMKF-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-3,5-dimethylbenzene Chemical group CC1=CC(C)=CC(C=2C=C(C)C=C(C)C=2)=C1 CMZYGFLOKOQMKF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 48
- 208000033679 diabetic kidney disease Diseases 0.000 abstract description 47
- 238000012360 testing method Methods 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 description 45
- 210000002700 urine Anatomy 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 44
- 238000000034 method Methods 0.000 description 28
- 102000008186 Collagen Human genes 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 26
- 229920001436 collagen Polymers 0.000 description 26
- 102000004401 podocalyxin Human genes 0.000 description 26
- 108090000917 podocalyxin Proteins 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 17
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 239000013641 positive control Substances 0.000 description 11
- 239000013642 negative control Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 8
- 238000013399 early diagnosis Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010001580 Albuminuria Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 206010027525 Microalbuminuria Diseases 0.000 description 5
- 230000024924 glomerular filtration Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000000585 glomerular basement membrane Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000009928 nephrosis Diseases 0.000 description 4
- 231100001027 nephrosis Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003990 molecular pathway Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000000557 podocyte Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000005234 proximal tubule cell Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Combination | Sensitivity | Specificity |
IV Collagen∪NGAL | 0.933 | 0.665 |
IV Collagen∩NGAL | 0.55 | 0.942 |
IV Collagen∪Podocalyxin | 0.92 | 0.594 |
IV Collagen∩Podocalyxin | 0.547 | 0.983 |
NGAL∪Podocalyxin | 0.968 | 0.615 |
NGAL∩Podocalyxin | 0.527 | 0.941 |
L-FABP∪Podocalyxin | 0.923 | 0.505 |
L-FABP∩Podocalyxin | 0.541 | 0.969 |
IV Collagen∪NGAL∪L-FABP∪Podocalyxin | 0.989 | 0.475 |
IV Collagen∩NGAL∩L-FABP∩Podocalyxin | 0.536 | 0.983 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201520168552.3U CN204479593U (en) | 2015-03-24 | 2015-03-24 | Based on the injury of kidney detection kit of biomarker |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201520168552.3U CN204479593U (en) | 2015-03-24 | 2015-03-24 | Based on the injury of kidney detection kit of biomarker |
Publications (1)
Publication Number | Publication Date |
---|---|
CN204479593U true CN204479593U (en) | 2015-07-15 |
Family
ID=53635380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201520168552.3U Expired - Fee Related CN204479593U (en) | 2015-03-24 | 2015-03-24 | Based on the injury of kidney detection kit of biomarker |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN204479593U (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016149971A1 (en) * | 2015-03-24 | 2016-09-29 | 深圳市贝沃德克生物技术研究院有限公司 | Diabetic nephropathy early detection reagent kit, biomarker testing method and applications |
WO2016149972A1 (en) * | 2015-03-24 | 2016-09-29 | 深圳市贝沃德克生物技术研究院有限公司 | Diabetic nephropathy early screening reagent kit, biomarker testing method and applications |
WO2017121001A1 (en) * | 2016-01-16 | 2017-07-20 | 深圳市华科安测信息技术有限公司 | Gold-labeled antibody test strip for use in early-stage diabetic nephropathy test |
WO2017202007A1 (en) * | 2016-05-24 | 2017-11-30 | 深圳市前海安测信息技术有限公司 | Method for preparing colloidal gold test strip for detection of early diabetic nephropathy |
-
2015
- 2015-03-24 CN CN201520168552.3U patent/CN204479593U/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016149971A1 (en) * | 2015-03-24 | 2016-09-29 | 深圳市贝沃德克生物技术研究院有限公司 | Diabetic nephropathy early detection reagent kit, biomarker testing method and applications |
WO2016149972A1 (en) * | 2015-03-24 | 2016-09-29 | 深圳市贝沃德克生物技术研究院有限公司 | Diabetic nephropathy early screening reagent kit, biomarker testing method and applications |
WO2017121001A1 (en) * | 2016-01-16 | 2017-07-20 | 深圳市华科安测信息技术有限公司 | Gold-labeled antibody test strip for use in early-stage diabetic nephropathy test |
WO2017202007A1 (en) * | 2016-05-24 | 2017-11-30 | 深圳市前海安测信息技术有限公司 | Method for preparing colloidal gold test strip for detection of early diabetic nephropathy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104764885A (en) | An early-stage screening kit for diabetic nephropathy, a biomarker detecting method and applications | |
Puthumana et al. | Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic review and meta-analysis | |
CN204479594U (en) | Based on the diabetic nephropathy early detection kit of biomarker | |
CN104764886A (en) | An early-stage detection kit for diabetic nephropathy, a biomarker detecting method and applications | |
CN204479593U (en) | Based on the injury of kidney detection kit of biomarker | |
Liu et al. | Methodological evaluation and comparison of five urinary albumin measurements | |
Huang et al. | A novel time-resolved fluoroimmunoassay for the quantitative detection of antibodies against the phospholipase A2 receptor | |
Li et al. | Urinary kidney injury molecule‑1 as an early indicator to predict contrast‑induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention | |
Wang et al. | Development of a novel chemiluminescence immunoassay for the detection of procalcitonin | |
Omoruyi et al. | Evaluation of the performance of urine albumin, creatinine and albumin–creatinine ratio assay on two POCT analyzers relative to a central laboratory method | |
Ghasemi et al. | Predictive accuracy of urinary neutrophil gelatinase associated lipocalin (NGAL) for renal parenchymal involvement in children with acute pyelonephritis | |
EP2442105B1 (en) | Test method on renal diseases | |
CN105699665A (en) | Detection kit of lipocalin related to neutrophil gelatinase | |
Ning et al. | Alpha1-antitrypsin in urinary extracellular vesicles: A potential biomarker of diabetic kidney disease prior to microalbuminuria | |
Kamel et al. | The potential use of urinary transferrin, urinary adiponectin, urinary Retinol Binding Protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: a case-control study | |
CN106066401A (en) | Biomarker VWF and ADAMTS13 and the purposes in liver cirrhosis diagnosis reagent thereof | |
CN103776914A (en) | Biomarker of male infertility in unknown aetiology and application method of biomarker | |
Chen et al. | A new criteria for screening macroprolactinemia using polyethylene glycol treatment combined with different assays for prolactin. | |
Wu et al. | Diagnostic value of progranulin in patients with lupus nephritis and its correlation with disease activity | |
CN105372431A (en) | Serum specific marker proteins for sarcoidosis and kit thereof | |
US20180275135A1 (en) | Biomarker panel to identify steroid resistance in childhood idiopathic nephrotic syndrome | |
JP2008002894A (en) | Disease-related proteins of nephritic syndrome and use thereof | |
JP2020106382A (en) | Method of detecting non-alcoholic steatohepatitis (nash) | |
Yu et al. | Establishment of Galectin-3 time-resolved fluoroimmunoassay and its application in idiopathic membranous nephropathy | |
US20230400466A1 (en) | Methods and systems for risk stratification and management of bladder cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SHENZHEN QIANHAIAN INFORMATION TECHNOLOGY CO., LTD. SHENZHEN BEIWODEKE BIO-TECHNOLOGY RESEARCH INSTITUTE CO., LTD. Effective date: 20150901 Owner name: SHENZHEN BEIWODEKE BIO-TECHNOLOGY RESEARCH INSTITU Free format text: FORMER OWNER: SHENZHEN YITEKE INFORMATION TECHNOLOGY CO., LTD. Effective date: 20150901 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150901 Address after: 518000 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A Patentee after: SHENZHEN BEIWO DEKE BIOTECHNOLOGY RESEARCH INSTITUTE CO., LTD. Address before: 518000 Guangdong city of Shenzhen province Nanshan District science and Technology Park high-tech South seven Digital Technology Park building B1 3B Patentee before: Shenzhen Yi Teke Information Technology Co., Ltd Patentee before: SHENZHEN QIANHAI ANCE INFORMATION TECHNOLOGY CO., LTD. Patentee before: SHENZHEN BEIWO DEKE BIOTECHNOLOGY RESEARCH INSTITUTE CO., LTD. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150715 Termination date: 20200324 |